Modulation of TRAIL-induced tumor cell apoptosis in a hypoxic environment

Cancer Biology and Therapy

Volumn 4, Issue 10, 2005, Pages 1068-1074

  Mayes, Patrick A ^a   Campbell, Latoya ^a   Ricci, M Stacey ^a   Plastaras, John P ^a   Dicker, David T ^a   El Deiry, Wafik S ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Apoptosis; Cancer therapy; Hif 1 ; Hypoxia; p53; Therapeutic resistance; TRAIL; Tumor microenvironment

Indexed keywords

DEFEROXAMINE; DOXORUBICIN; PROTEIN HIF 1 ALPHA; PROTEIN P53; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; BLOOD LEVEL; CANCER CELL; CELL LINE; CELL SURVIVAL; COLON CARCINOMA; COMPARATIVE STUDY; HUMAN; HUMAN CELL; HYPOXIA; LUNG CANCER; MICROENVIRONMENT; OSTEOSARCOMA; OVARY TERATOMA; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; TERATOCARCINOMA; TUMOR CELL; WILD TYPE;

EID: 27744559977     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.4.10.2255     Document Type: Article

References (27)

1. Harris AL. Hypoxia - a key regulatory factor in tumour growth. Nat Rev Cancer 2002; 2:38-47.
2. Semenza GL. Targeting Hif-1α-1 for cancer therapy. Nat Rev Cancer 2003; 3:721-32.
3. Maxwell P, Salnikow K. HIF-1: an oxygen and metal responsive transcription factor. Cancer Biol Ther 2004; 3:29-35.
4. Giaccia A, Siim BG, Johnson RS. HIF-1 as a target for drug development. Nat Rev Drug Discov 2003; 2:803-11.
5. Fei P, Wang W, Kim S, Wang S, Burns TF, Sax JK, Buzzai M, Dicker DT, McKenna WG, Bernhard EJ, El-Deiry WS. Bnip3L is induced by p53 under hypoxia, and its knockdown promotes tumor growth. Cancer Cell 2004; 6:597-609.
6. El-Deiry WS. Insights into cancer therapeutic design based on p53 and TRAIL receptor signaling. Cell Death Differ 2001; 8:1066-75.
7. Kelly SK, Ashkenazi A. Targeting death receptors in cancer with Apo2L/TRAIL. Curr Opin Pharmacol 2004; 4:333-9.
8. Ricci MS, Jin Z, Dews M, Yu D, Thomas-Tikhonenko A, Dicker DT, El-Deiry WS. Direct repression of FLIP expression by c-myc is a major determinant of TRAIL sensitivity. Mol Cell Biol 2004; 24:8541-55.
9. Wang S, El-Deiry WS. TRAIL and apoptosis induction by TNF-family death receptors. Oncogene 2003; 22:8628-33.
10. Kim K, Takimoto R, Dicker DT, Chen Y, Gazitt Y, El-Deiry WS. Enhanced TRAIL sensitivity by p53 overexpression in human cancer but not normal cell lines. Int J Oncol.2001; 18:241-7.
11. Kim K, Fisher MJ, Xu SQ, El-Deiry WS. Molecular determinants of response to TRAIL in killing of normal and cancer cells. Clin Cancer Res 2000; 6:335-46.
12. Kim K, Nakagawa H, Fei P, Rustgi AK, El-Deiry WS. Targeting Bcl-xL in esophageal squamous cancer to sensitize to chemotherapy plus TRAIL-induced apoptosis while normal epithelial cells are protected by blockade of caspase 9. Cell Death Differ 2004; 5:583-7.
13. Deng Y, Lin Y, Wu X. TRAIL-induced apoptosis requires Bax-dependent mitochondrial release of Smac/DIABLO. Genes Dev 2002; 16:33-45.
14. Wang Z, Cuddy M, Samuel T, Welsh K, Schimmer A, Hanaii F, Houghten R, Pinilla C, Reed JC. Cellular, biochemical, and genetic analysis of mechanism of small molecule IAP inhibitors. J Biol Chem 2004; 279:48168-76.
15. Schimmer AD, Welsh K, Pinilla C, Wang Z, Krajewska M, Bonneau MJ, Pedersen IM, Kitada S, Scott FL, Bailly-Maitre B, Glinsky G, Scudiero D, Sausville E, Salvesen G, Nefzi A, Ostresh JM, Houghten RA, Reed JC. Small-molecule antagonists of apoptosis suppressor XIAP exhibit broad antitumor activity. Cancer Cell 2004; 5:25-35.
16. Park SY, Billiar TR, Seol DW. Hypoxia inhibition of apoptosis induced by tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). Biochem Biophys Res Commun 2002; 291:150-3.
17. Kim M, Park SY, Pai HS, Kim TH, Billiar TR, Seol DW. Hypoxia inhibits tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by blocking Bax translocation. Cancer Res 2004; 64:4078-81.
18. Weinmann M, Marini P, Jendrossek V, Betsch A, Goecke B, Budach W, Belka C. Influence of hypoxia on TRAIL-induced apoptosis in tumor cells. Int J Radiat Oncol Biol Phys 2004; 58:386-96.
19. Ravi R, Mookerjee B, Bhujwalla ZM, Sutter CH, Artemov D, Zeng Q, Dillehay LE, Madan A, Semenza GL, Bedi A. Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1α. Genes Dev 2000; 14:34-44.
20. Hockel M, Vaupel P. Tumor hypoxia: definitions and current clinical, biological, and molecular aspects. J. Natl. Cancer Inst 2001; 93:266-76.
21. Hammond EM, Giaccia AJ. The role of p53 in hypoxia-induced apoptosis. Biochem Biophys Res Commun 2005; 331:718-25.
22. Fillies T, Werkmeister R, van Diest PJ, Brandt B, Joos U, Buerger H. Hif-1α overexpression indicates a good prognosis in early stage squamous cell carcinomas of the oral floor. BMC Cancer 2005; 5:84.
23. Nakanishi K, Hiroi S, Tominaga S, Aida S, Kasamatsu H, Matsuyama S, Matsuyama T, Kawai T. Expression of hypoxia-inducible factor-1α protein predicts survival in patients with transitional cell carcinoma of the upper urinary tract. Clin Cancer Res 2005; 11:2583-90.
24. Vaupel P, Mayer A. Hypoxia and anemia: effects on tumor biology and treatment resistance. Transfus Clin Biol 2005; 12:5-10.
25. Peters KB, Brown JM. Tirapazamine: A Hypoxia-activated Topoisomerase II Poison. Cancer Res. 2002; 62:5248-53.
26. Brown JM, Wilson WR. Exploiting tumour hypoxia in cancer treatment. Nat Rev Cancer. 2004; 4:437-47.
27. Dicker DT, El-Deiry WS. Flow cytometric analysis of tumor suppressor gene-induced apoptosis. Methods Mol Biol. 2003; 223:271-82.